Engensis
- Generic Name
- Engensis
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 5WL65F3KCB
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT04873232
- Locations
- ๐บ๐ธ
Arizona Research Center, Phoenix, Arizona, United States
๐บ๐ธClinical Trials - Little Rock, Little Rock, Arkansas, United States
๐บ๐ธCalifornia Medical Clinic for Headache, Los Angeles, California, United States
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04632225
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธJohns Hopkins University Department of Neurology, Baltimore, Maryland, United States
๐บ๐ธSt. Joseph's Hospital and Medical Center, Barrows Neurological Institute, Phoenix, Arizona, United States
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- Other: Placebo
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT04469270
- Locations
- ๐บ๐ธ
Futuro Clinical Trials, LLC, McAllen, Texas, United States
๐บ๐ธArizona Research Center, Phoenix, Arizona, United States
๐บ๐ธClinical Trials - Little Rock, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.